Michael Hunt, CFO at ReNeuron Group Plc (LON:RENE) chats to Proactive to update on the cell-based therapeutics specialist's research and development programmes.
Hunt says they're to increase the number of clinical sites in their PISCES III study from 25 to 40.
PISCES III is a phase IIb clinical study in the US of ReNeuron's CTX cell therapy candidate for stroke disability.
First patient dosing in the study is expected in mid-2018 and top-line data from the study, as previously indicated, is expected in late 2019.
Meet ANGLE plc, Faron Pharmaceuticals Ltd, Alliance Pharma plc, Clinigen Group PLC and Avacta Group Plc at our event,London, 05 April 2018.Register here >>